Shieldin complex promotes DNA end-joining and counters homologous recombination in BRCA1-null cells
Harveer Dev(University of Cambridge), Ting-Wei Chiang(University of Cambridge), Chloé Lescale(Institut Pasteur), Inge de Krijger(The Netherlands Cancer Institute), Alistair Martin(University of Cambridge), Domenic Pilger(University of Cambridge), Julia Coates(University of Cambridge), Matylda Sczaniecka-Clift(University of Cambridge), Wenming Wei(Institut Pasteur), Matthias Ostermaier(Institute of Molecular Biology), Mareike Herzog(University of Cambridge), Jonathan Lam(University of Cambridge), Abigail Shea(University of Cambridge), Mukerrem Demir(University of Cambridge), Qian Wu(University of Cambridge), Fengtang Yang(Wellcome Sanger Institute), Beiyuan Fu(Wellcome Sanger Institute), Zhongwu Lai(AstraZeneca (United States)), Gabriel Balmus(University of Cambridge), Rimma Belotserkovskaya(University of Cambridge), Violeta Serra(Vall d'Hebron Institute of Oncology), Mark J. O’Connor(AstraZeneca (United Kingdom)), Alejandra Bruna(University of Cambridge), Petra Beli(Institute of Molecular Biology), Luca Pellegrini(University of Cambridge), Carlos Caldas(University of Cambridge), Ludovic Deriano(Institut Pasteur), Jacqueline J.L. Jacobs(The Netherlands Cancer Institute), Yaron Galanty(University of Cambridge), Stephen P. Jackson(University of Cambridge)
Cited by 417Open Access